Letter to the Editor “Increased sensitivity to ischemic interval of donor hearts with diminished left ventricular function”
The recent publication by Davila et al evaluated the impact of donor left ventricular ejection fraction (LVEF) on the association between risk factors of 1-year mortality post heart transplantation and post-transplant outcomes. 1 The authors developed multivariable cox regression models including variables related to donor and recipient characteristics, stratified their models by the donor LVEF groups, and compared the observed associations from each strata. By doing so, the authors concluded that in subgroups of recipients transplanted with reduced LVEF donors, the association between ischemic time and 1-year mortality is stronger.
AbstractPurpose of the ReviewAlthough still a relatively new technology, long-term left ventricular assist devices (LVADs) for management of advanced heart failure is rapidly increasing. Initially designed as a bridge to transplant, these invasive devices are increasingly used as a destination therapy, creating unique and long-term infection risks. The aim of this comprehensive review is to highlight current evidence about the prevention, diagnosis, and management of LVAD-specific infections.Recent FindingsThere are two recent, major societal guidelines (The International Society for Heart and Lung Transplantation, 2017, a...
CONCLUSION: The future of organ bioengineering relies on furthering understanding of organogenesis, in vivo regeneration, regenerative immunology and long-term monitoring of implanted bioengineered organs. PMID: 32463143 [PubMed - in process]
We report a case of 2019-nCoV pneumonia with associated acute myocardial injury2 confirmed by biomarkers as well as cardiac Magnetic Resonance Imaging (MRI).
Publication date: Available online 27 May 2020Source: Respiratory Medicine Case ReportsAuthor(s): Lea Deterding, Tina Körner, Gudrun Borte, Hubert Wirtz, Hans-Jürgen Seyfarth
Of the four major solid organ transplants, median survival following lung transplantation (LTx) remains the shortest (5.7-5.8 years) with negligible improvements reported over the last decade due to high rates of chronic lung allograft dysfunction (CLAD), a progressive and ultimately fatal complication limiting long-term survival in transplantees.1 Bronchiolitis obliterans syndrome (BOS), often dubbed the “Achilles Heel” of lung transplantation, is the most common manifestation of CLAD and is resistant to most current treatment modalities, leaving repeat lung transplantation (re-LTx) the only treatment option.
Abstract Rescuing patients with the development of acute respiratory distress syndrome and right heart failure after left ventricular assist device placement remains a challenge in patients with congenital heart disease. TandemLife Protek Duo (TandemLife, Pittsburg, PA) is a double-lumen cannula introduced via the internal jugular vein that can provide veno-venous extra-corporeal membrane oxygenation and right heart support. To our knowledge, we report the first case of successfully using the TandemLife Protek Duo cannula to provide veno-venous extra-corporeal membrane oxygenation and right ventricle support in an...
Post-lung transplantation (post-LTx) progressive chronic kidney disease (CKD) is associated with increased morbidity and mortality.1 Comorbidities and cotreatments, and post-LTx medical complications, including acute kidney injury (AKI), are associated with an increased risk for subsequent CKD development.2 However, among the several risk factors for post-LTx CKD development, pre-transplant renal function plays a key role.3